$27.90
-3.73[-11.79%]
Last update: 3:08PM Get Real Time Here
Integra Lifesciences
(NASDAQ:IART)Integra Lifesciences Stock (NASDAQ:IART), Analyst Ratings, Price Targets, Predictions
Integra Lifesciences Holdings Corp has a consensus price target of $45.15, established from looking at the 41 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Truist Securities, and JMP Securities on April 3, 2024, March 1, 2024, and February 29, 2024. With an average price target of $42.67 between Citigroup, Truist Securities, and JMP Securities, there's an implied 52.93% upside for Integra Lifesciences Holdings Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Truist Securities
JMP Securities
Wells Fargo
CL King
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Integra Lifesciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | IART | Buy Now | Integra Lifesciences | $27.90 | 36.2% | Citigroup | Joanne Wuensch | $38 → $38 | Upgrade | Sell → Neutral | Get Alert |
| 03/01/2024 | IART | Buy Now | Integra Lifesciences | $27.90 | 46.95% | Truist Securities | Richard Newitter | $46 → $41 | Maintains | Hold | Get Alert |
| 02/29/2024 | IART | Buy Now | Integra Lifesciences | $27.90 | 75.63% | JMP Securities | David Turkaly | $55 → $49 | Maintains | Market Outperform | Get Alert |
| 12/22/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 64.87% | Truist Securities | Richard Newitter | $44 → $46 | Maintains | Hold | Get Alert |
| 12/14/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 57.71% | Truist Securities | Richard Newitter | $39 → $44 | Maintains | Hold | Get Alert |
| 12/14/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 97.13% | JMP Securities | David Turkaly | → $55 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/05/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 75.63% | Wells Fargo | Larry Biegelsen | $40 → $49 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/14/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 79.21% | CL King | Kristen Stewart | → $50 | Initiates | → Buy | Get Alert |
| 10/26/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 39.78% | Truist Securities | Richard Newitter | $41 → $39 | Maintains | Hold | Get Alert |
| 10/26/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 32.62% | Morgan Stanley | Drew Ranieri | $44 → $37 | Maintains | Underweight | Get Alert |
| 08/24/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 57.71% | Morgan Stanley | Drew Ranieri | → $44 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 07/28/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 115.05% | JMP Securities | David Turkaly | $65 → $60 | Maintains | Outperform | Get Alert |
| 07/19/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 72.04% | Truist Securities | Richard Newitter | $44 → $48 | Maintains | Hold | Get Alert |
| 07/12/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 89.96% | Jefferies | Matthew Taylor | $58 → $53 | Upgrade | Hold → Buy | Get Alert |
| 06/08/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | — | Argus Research | David Toung | — | Downgrade | Buy → Hold | Get Alert |
| 05/31/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 54.12% | Morgan Stanley | Drew Ranieri | $59 → $43 | Maintains | Equal-Weight | Get Alert |
| 05/30/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 57.71% | Truist Securities | Richard Newitter | $54 → $44 | Reiterates | Hold → Hold | Get Alert |
| 05/26/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 132.97% | JMP Securities | David Turkaly | → $65 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/24/2023 | IART | Buy Now | Integra Lifesciences | $27.90 | 54.12% | JP Morgan | Robbie Marcus | $56 → $43 | Downgrade | Neutral → Underweight | Get Alert |
FAQ
What is the target price for Integra Lifesciences (IART)?
The latest price target for Integra Lifesciences (NASDAQ: IART) was reported by Citigroup on April 3, 2024. The analyst firm set a price target for $38.00 expecting IART to rise to within 12 months (a possible 36.20% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Integra Lifesciences (IART)?
The latest analyst rating for Integra Lifesciences (NASDAQ: IART) was provided by Citigroup, and Integra Lifesciences upgraded their neutral rating.
When was the last upgrade for Integra Lifesciences (IART)?
The last upgrade for Integra Lifesciences Holdings Corp happened on April 3, 2024 when Citigroup raised their price target to $38. Citigroup previously had a sell for Integra Lifesciences Holdings Corp.
When was the last downgrade for Integra Lifesciences (IART)?
The last downgrade for Integra Lifesciences Holdings Corp happened on August 24, 2023 when Morgan Stanley changed their price target from N/A to $44 for Integra Lifesciences Holdings Corp.
When is the next analyst rating going to be posted or updated for Integra Lifesciences (IART)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Integra Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Integra Lifesciences was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Integra Lifesciences (IART) correct?
While ratings are subjective and will change, the latest Integra Lifesciences (IART) rating was a upgraded with a price target of $38.00 to $38.00. The current price Integra Lifesciences (IART) is trading at is $27.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.